2020
Association of pre-existing mental illness with all-cause and cancer-specific mortality among Medicare beneficiaries with pancreatic cancer
Paredes AZ, Hyer JM, Tsilimigras DI, Palmer E, Lustberg MB, Dillhoff ME, Cloyd JM, Tsung A, Ejaz A, Wells-Di Gregorio S, Pawlik TM. Association of pre-existing mental illness with all-cause and cancer-specific mortality among Medicare beneficiaries with pancreatic cancer. Hepato Pancreato Biliary 2020, 23: 451-458. PMID: 32843275, DOI: 10.1016/j.hpb.2020.08.002.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAgedHumansMedicareMental DisordersPancreatic NeoplasmsRetrospective StudiesUnited StatesConceptsCancer-specific mortalityLong-term outcomesPancreatic cancerMental illnessPre-existing mental illnessSchizophrenic disordersHigh riskMedicare beneficiariesCancer-directed surgerySEER-Medicare databasePre-existing historyAnxiety/depressionEarly-stage cancerCause mortalityMultivariable analysisPancreatic adenocarcinomaStage cancerPsychotic disordersPatientsBipolar disorderIllnessCancerMortalityDisordersDepressionRacial/Ethnic Disparities in Hospice Utilization Among Medicare Beneficiaries Dying from Pancreatic Cancer
Paredes AZ, Hyer JM, Palmer E, Lustberg MB, Pawlik TM. Racial/Ethnic Disparities in Hospice Utilization Among Medicare Beneficiaries Dying from Pancreatic Cancer. Journal Of Gastrointestinal Surgery 2020, 25: 155-161. PMID: 32193849, DOI: 10.1007/s11605-020-04568-9.Peer-Reviewed Original ResearchMeSH KeywordsAgedEthnicityFemaleHealthcare DisparitiesHospicesHumansMaleMedicareMinority GroupsPancreatic NeoplasmsUnited StatesConceptsEthnic minority patientsPancreatic cancerHospice utilizationMinority patientsHospice servicesWhite patientsMedicare Standard Analytic FilesRacial/Ethnic DisparitiesStandard Analytic FilesDeceased individualsTime of deathOverall low useClinical factorsMost patientsMultivariable analysisAnalytic FilesMedicare beneficiariesPancreatectomyPatientsComparable oddsEthnic disparitiesCancerLogistic regressionLow useDeath
2015
Biomodulation of capecitabine by paclitaxel and carboplatin in advanced solid tumors and adenocarcinoma of unknown primary
Mikhail S, Lustberg M, Ruppert A, Mortazavi A, Monk P, Kleiber B, Villalona-Calero M, Bekaii-Saab T. Biomodulation of capecitabine by paclitaxel and carboplatin in advanced solid tumors and adenocarcinoma of unknown primary. Cancer Chemotherapy And Pharmacology 2015, 76: 1005-1012. PMID: 26416564, DOI: 10.1007/s00280-015-2877-6.Peer-Reviewed Original ResearchMeSH KeywordsActivation, MetabolicAdenocarcinomaAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCapecitabineCarboplatinDisease-Free SurvivalDose-Response Relationship, DrugDrug Administration ScheduleEnzyme InductionEsophageal NeoplasmsFatigueFemaleGene Expression Regulation, NeoplasticHematologic DiseasesHumansKaplan-Meier EstimateMaleMaximum Tolerated DoseMiddle AgedNeoplasmsNeoplasms, Unknown PrimaryPaclitaxelPancreatic NeoplasmsProdrugsThymidine PhosphorylaseTreatment OutcomeUp-RegulationYoung AdultConceptsAdvanced solid tumorsII studyUnknown primaryDay 1Phase I/II studySolid tumorsPhase IPhase II patientsAntitumor activityObjective response ratePhase II dosePhase II studyMaximal tolerable doseSynergistic antitumor activityCessation of fundingCapecitabine 750Paclitaxel 60Disease stabilizationAcceptable tolerabilityAdvanced adenocarcinomaPartial responseCarboplatin AUCII patientsTolerable dosePatients